On July 20, Akeso rose 3.17% in regular trading, trading at HK$91.55/share, with turnover of HK$159 million. The gain was driven by a broad rally across the biotechnology sector.

On the news front, multiple brokerages have recently reaffirmed their bullish stance on the company. CITIC Construction maintained a Buy rating, highlighting the companys globally leading Tetrabody bispecific antibody technology platform and its established IO 2.0 + ADC dual strategic direction. Zhongtai Securities also initiated coverage with a Buy rating, noting that core bispecific antibody pipelines are poised to redefine treatment standards.

Within the Biotechnology sector, gains were widespread. Among individual stocks, REMEGEN rose 6.43%, SKB BIO rose 5.78%, INNOVENT BIO rose 4.1%, BEIGENE rose 3.77%, and 3SBIO rose 3.65%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)